Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage

Journal of Inherited Metabolic Disease

Volumn 31, Issue SUPPL. 2, 2008, Pages

  Wang, R Y ^a   Abe, J T ^b   Cohen, A H ^c   Wilcox, W R ^c  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^b Peninsula Pulmonary Institute   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE BETA; ALPHA GALACTOSIDASE; CERAMIDE TRIHEXOSIDE; GLOBOTRIAOSYLCERAMIDE; ISOENZYME;

ARTICLE; BIOPSY; BIOSYNTHESIS; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; ENZYME REPLACEMENT; ENZYMOLOGY; FABRY DISEASE; FEMALE; GENETICS; HUMAN; LUNG; LUNG FIBROSIS; LUNG FUNCTION TEST; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ALPHA-GALACTOSIDASE; BIOPSY; DNA MUTATIONAL ANALYSIS; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; ISOENZYMES; LUNG; LUNG DISEASES, OBSTRUCTIVE; MIDDLE AGED; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TRIHEXOSYLCERAMIDES;

EID: 84879791335     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-008-0930-x     Document Type: Article

References (27)

1. Amir G, Ron N (1999) Pulmonary pathology in Gaucher's disease. Hum Pathol 30(6):666-670. doi:10.1016/S0046-8177 (99) 90092-8.
2. Baehner F, Kampmann C, Whybra C, et al (2003) Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis 26:617-627. doi:10.1023/B:BOLI.0000005658.14563.77.
3. Bagdade JD, Parker F, Ways PO, et al (1968) Fabry's disease: a correlative clinical, morphologic, and biochemical study. Lab Invest 18(6):681-688.
4. Bartimmo EE, Guisan M, Moser KM (1972) Pulmonary involvement in Fabry's disease: a reappraisal. Am J Med 53:755-764. doi:10.1016/0002-9343 (72) 90194-5.
5. Bierer G, Kamangar N, Balfe D, et al (2005) Cardiopulmonary exercise testing in Fabry disease. Respiration 72:504-511. doi:10.1159/000087675.
6. Bierer G, Balfe D, Wilcox WR, et al (2006) Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease. J Inherit Metab Dis 29:572-579. doi:10.1007/s10545-006-0361-5.
7. Brown LK, Miller A, Bhuptani A, et al (1997) Pulmonary involvement in Fabry disease. Am J Respir Crit Care Med 155:1004-1010.
8. Eng CM, Banikazemi M, Gordon RE, et al (2001a) A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68(3):711-722. doi:10.1086/318809.
9. Eng CM, Guffon N, Wilcox WR, et al (2001b) Safety and efficacy of recombinant human a-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345(1):9-16. doi:10.1056/NEJM200107053450102.
10. Germain DP, Waldek S, Banikazemi M, et al (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18:1547-1557. doi:10.1681/ASN.2006080816.
11. Heare T, Alp NJ, Priestman DA, et al (2007) Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment. J Inherit Metab Dis 30:79-87. doi:10.1007/s10545-006-0473-y.
12. Kalliokoski RJ, Kalliokoski KK, Penttinen M, et al (2006) Structural and functional changes in peripheral vasculature of Fabry patients. J Inherit Metab Dis 29:660-666. doi:10.1007/s10545-006-0340-x.
13. Kariman K, Singletary WV, Sieker HO (1978) Pulmonary involvement in Fabry's disease. Am J Med 64:911-912. doi:10.1016/0002-9343 (78) 90542-9.
14. Kelly MM, Leigh R, McKenzie R, et al (2000) Induced sputum examination: diagnosis of pulmonary involvement in Fabry's disease. Thorax 55:720-721. doi:10.1136/thorax.55.8.720.
15. Kerem E, Elstein D, Abrahamov A, et al (1996) Pulmonary function abnormalities in type I Gaucher disease. Eur Respir J 9(2):340-345. doi:10.1183/09031936.96.09020340.
16. Kim W, Pyeritz RE, Bernhardt BA, Casey M, Litt HI (2007) Pulmonary manifestations of Fabry diease and positive response to enzyme replacement therapy. Am J Med Genet A 143 A: 377-381. doi:10.1002/ajmg.a.31600.
17. Magage S, Lubanda JC, Susa Z, et al (2007) Natural history of the respiratory involvement in Anderson-Fabry disease. J Inherit Metab Dis 30:790-799. doi:10.1007/s10545-007-0616-9.
18. Matsumoto T, Matsumori H, Taki T, et al (1979) Infantile GM1-gangliosidosis with marked manifestation of lungs. Acta Pathol Jpn 29(2):269-276.
19. Miller MR, Hankinson J, Brusasco V, et al (2005) Standardisation of spirometry. Eur Resp J 26:319-338. doi:10. 1183/09031936.05.00034805.
20. Nicholson AG, Florio R, Hansell DM, et al (2006) Pulmonary involvement by Niemann-Pick disease. A report of six cases. Histopathology 48(5):596-603. doi:10.1111/j.1365-2559.2006.02355.x.
21. Rosenberg DM, Ferrans VJ, Fulmer JD, et al (1980) Chronic airflow obstruction in Fabry's disease. Am J Med 68:898-905. doi:10.1016/0002-9343 (80) 90224-7.
22. Schiffmann R, Murray GJ, Treco D, et al (2000) Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 97(1):365-370. doi:10.1073/pnas.97.1. 365.
23. Schiffmann R, Kopp JB, Austin HA, et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743-2749. doi:10.1001/jama.285.21.2743.
24. Smith P, Heath D, Rodgers B, et al (1991) Pulmonary vasculature in Fabry's disease. Histopathology 19:567-569. doi:10.1111/j.1365-2559.1991. tb01510.x.
25. Wang RY, Lelis A, Mirocha J, et al (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 9(1):34-45. doi:10.1097/GIM.0b013e31802d8321.
26. Wilcox WR, Oliveira JP, Hopkin RJ, et al (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93(2):112-128. doi:10.1016/j.ymgme.2007.09.013.
27. Weidemann F, Breunig F, Beer M, et al (2005) The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 26:1221-1227.